Pay in 4 interest-free payments of $5.82 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Reviewed by: FormBlends Medical Team | Last updated: May 29, 2026 | Sources: USP general chapters, FDA compounding guidance, peer-reviewed GLP-1/GIP pharmacology literature, manufacturer prescribing information
Start the provider review Evidence check Useful peptide pages should separate human data, animal research, mechanistic evidence, and marketing claims
Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
Each vial meets USP specifications for sterility, endotoxin limits, and particulate matter, ensuring consistent and reliable performance in research applications
Green R, et al
Nonetheless, state rules can impose some extra limitations depending on the purpose of use
US$ 28.02
US$ 20.40
US$ 20.41
US$ 21.69
US$ 27.64
US$ 20.91
US$ 29.05
US$ 29.13
